Related Experiment Video
Updated: Jan 8, 2026

An In Vitro Batch-culture Model to Estimate the Effects of Interventional Regimens on Human Fecal Microbiota
Published on: July 31, 2019
Antibiotic-induced gut microbiota depletion enhances glucose tolerance linked to GLP-1 signaling
Alexandra Kellenberger1, Revati Sumukh Dewal1, Alice de Wouters d'Oplinter2
1Laboratory of Translational Nutrition Biology, Department of Health Sciences and Technology, Institute of Food, Nutrition and Health, ETH Zurich, Schwerzenbach, Switzerland.
Introduction:
Depletion of the gut microbiota is known to improve glucose metabolism and modify thermogenic capacity in mice. However, the underlying mechanisms remain unclear. In this study, we aimed to determine whether the browning effect observed after antibiotic treatment contributes to metabolic modifications and to investigate the potential central role of GLP-1 in enhancing glucose metabolism.
Methods:
Using an inducible Ucp1DTR mouse model to transiently ablate UCP1+ cells, we assessed glucose tolerance, cold sensitivity, and circulating GLP-1 levels following gut microbiota depletion. We additionally examined GLP-1 levels in germ-free mice. Glucose tolerance was compared to GLP1R KO mice following gut microbiota depletion. Bile acid profiling in wild-type mice treated with antibiotics identified regulated bile acids, which were subsequently tested in an in vitro STC-1 cell assay and in vivo in Cyp2c70 mice to identify potential basal GLP-1 secretion inhibitors.
Results:
We demonstrate that gut microbiota depletion improved glucose tolerance independent of UCP1+ cell presence and increased cold sensitivity. Antibiotic treatment increased circulating active GLP-1 levels within one day, and this increase was also observed in germ-free mice, supporting the suggestion that GLP-1 elevation is driven by gut microbiota depletion. The improvement in glucose tolerance was lost in GLP1R KO mice upon oral glucose ingestion. Bile acid profiling and subsequent validation led to the identification of two potential basal GLP-1 secretion inhibitors.
Discussion:
Our findings suggest that the metabolic improvements following gut microbiota depletion are primarily driven by GLP-1 signaling, rather than UCP1⁺ cell activation. These results highlight the complex interplay between the gut microbiome and metabolic health, offering insights into potential therapeutic targets for improving glucose metabolism through modulation of basal GLP-1 signaling.
Related Concept Videos
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are...
Oral Hypoglycemic Agents: Biguanides and Glitazones
Dipeptidyl Peptidase 4 Inhibitors
Glucose Absorption Into the Small Intestine
Glucose Transporters
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:

